Dr. Bell's addition to OmniScience's leadership team signifies a major step forward in the company's commitment to developing cutting-edge platforms that will shape the future of data science in the life sciences industry.

In his role as Vice President of Platforms, Dr. Bell will be at the forefront of driving innovation and excellence in OmniScience's platform development efforts. With his extensive background and academic achievements, Dr. Bell is poised to lead the company into an era of unparalleled platform advancements.

Dr. Bell brings a wealth of experience to his new role. He most recently served as Chief Data Scientist for Teknoir where he guided its AI/ML strategy and led the development and delivery of applications to improve safety and productivity. Prior to Teknoir, he served as Principal Consultant and Director of Technology at . Dr. Bell brings a combination of domain expertise in the architecture of production-grade AI/ML systems and extensive experience developing platforms for clinical research, discovery, and validation. His academic qualifications include a Ph.D. in Quantitative and Computational Biosciences from Baylor College of Medicine. Dr. Bell's expertise in product development, coupled with his passion for pioneering technologies, perfectly align with OmniScience's mission to create revolutionary solutions.

Angela Holmes, CEO of OmniScience, emphasized the significance of this appointment stating, "We are thrilled to welcome Dr. Michael Bell to our team. His appointment as Vice President of Platforms is a testament to our commitment to innovation and growth. Dr. Bell's extensive background in platform development, coupled with his deep understanding of AI and biology, will undoubtedly drive OmniScience to new heights. We look forward to the opportunities that his leadership will unlock for our company."